Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Fabrazyme versus Replagal in adults with Fabry disease
NL-OMON24907Active, not recruiting
- Sponsor
- Sponsor: College voor Zorgverzekeringen (dutch health care insurance board). Initiator: Dr. C.E.M. Hollak, internist Dept. of Internal Medicine, F4-279 Academic Medical Center PO box 22660 1100 DD Amsterdam The Netherlands tel. +31-20-5666071 fax: +31-20-6919743 e-mail: [email protected]
- Start
- May 2002
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of agalsidase beta and agalsidase alfa in Fabry disease (FD) (2 arms), sponsored by Sponsor: College voor Zorgverzekeringen (dutch health care insurance board). Initiator: Dr. C.E.M. Hollak, internist Dept. of Internal Medicine, F4-279 Academic Medical Center PO box 22660 1100 DD Amsterdam The Netherlands tel. +31-20-5666071 fax: +31-20-6919743 e-mail: [email protected]. Primary endpoint: Cardiac wall thickness and end-diastolic volume on echocardiography. Started May 2002; status: active, not recruiting.
02
Drugs
agalsidase betaagalsidase alfa
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NL-OMON24907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24907.